In two studies of patients with *Candida* bloodstream infections, delays of 12-14 hours resulted in a mortality rate 2-3 times higher compared to patients who received more timely antifungal therapy.\(^1\,2\)

**VITEK®2 AST-YS08 CARD OFFERS:**

- 4 antifungals with improved performance\(\dagger\)
- Results in as little as 6 hours\(\star\)
- Reduced hands-on-time compared to other automated systems \(^3\,5\)
- Rapid, automated and standardized testing taking subjectivity out of antifungal AST

**REFERENCES**

6. Pfaler MA, Dreikorn DJ, Procop GW, Wiederhold NP, JCM 2014; 52(6):2126-2130

\(\dagger\) New redeveloped versions

\(\star\) Not available in the United States. Availability elsewhere pending local regulatory clearance.

\(\star\star\) Based on clinical trial data.

**VITEK®2 AST-YS08**

Ref. 420739*

- **Amphotericin B**
- **Caspofungin\(\dagger\)**
- **Fluconazole\(\dagger\)**
- **Flucytosine\(\dagger\)**
- **Micafungin\(\dagger\)**
- **Voriconazole**

\(\dagger\) New redeveloped versions

* Not available in the United States. Availability elsewhere pending local regulatory clearance.

**Based on clinical trial data.

Contact your bioMérieux representative for availability